These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 11691563)
1. Hamao Umezawa Memorial Award Lecture: "An Odyssey in the Viral Chemotherapy Field". De Clercq E Int J Antimicrob Agents; 2001 Oct; 18(4):309-28. PubMed ID: 11691563 [TBL] [Abstract][Full Text] [Related]
2. Selective virus inhibitors. De Clercq E Microbiologica; 1990 Apr; 13(2):165-78. PubMed ID: 1693749 [TBL] [Abstract][Full Text] [Related]
3. Antiviral drug discovery and development: where chemistry meets with biomedicine. De Clercq E Antiviral Res; 2005 Aug; 67(2):56-75. PubMed ID: 16046240 [TBL] [Abstract][Full Text] [Related]
4. The antiviral spectrum of (E)-5-(2-bromovinyl)-2'-deoxyuridine. De Clercq E J Antimicrob Chemother; 1984 Aug; 14 Suppl A():85-95. PubMed ID: 6092320 [TBL] [Abstract][Full Text] [Related]
5. 5-(1-Substituted) alkyl pyrimidine nucleosides as antiviral (herpes) agents. Kumar R Curr Med Chem; 2004 Oct; 11(20):2749-66. PubMed ID: 15544474 [TBL] [Abstract][Full Text] [Related]
6. The antiviral activity and mechanism of action of (S)-[3-hydroxy-2-(phosphonomethoxy)propyl] (HPMP) nucleosides. Magee WC; Evans DH Antiviral Res; 2012 Nov; 96(2):169-80. PubMed ID: 22960154 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses. Hakimelahi GH; Ly TW; Moosavi-Movahedi AA; Jain ML; Zakerinia M; Davari H; Mei HC; Sambaiah T; Moshfegh AA; Hakimelahi S J Med Chem; 2001 Oct; 44(22):3710-20. PubMed ID: 11606136 [TBL] [Abstract][Full Text] [Related]
9. 2001 ASPET Otto Krayer Award Lecture. Molecular targets for antiviral agents. De Clercq E J Pharmacol Exp Ther; 2001 Apr; 297(1):1-10. PubMed ID: 11259521 [TBL] [Abstract][Full Text] [Related]
10. Stealth nucleosides: mode of action and potential use in the treatment of viral diseases. Daifuku R BioDrugs; 2003; 17(3):169-77. PubMed ID: 12749753 [TBL] [Abstract][Full Text] [Related]
11. Acyclic nucleoside phosphonates: a key class of antiviral drugs. De Clercq E; Holý A Nat Rev Drug Discov; 2005 Nov; 4(11):928-40. PubMed ID: 16264436 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections. De Clercq E Verh K Acad Geneeskd Belg; 1996; 58(1):19-47; discussion 47-9. PubMed ID: 8701600 [TBL] [Abstract][Full Text] [Related]
14. Curious discoveries in antiviral drug development: the role of serendipity. De Clercq E Med Res Rev; 2015 Jul; 35(4):698-719. PubMed ID: 25726922 [TBL] [Abstract][Full Text] [Related]
18. Antiviral activity of hop constituents against a series of DNA and RNA viruses. Buckwold VE; Wilson RJ; Nalca A; Beer BB; Voss TG; Turpin JA; Buckheit RW; Wei J; Wenzel-Mathers M; Walton EM; Smith RJ; Pallansch M; Ward P; Wells J; Chuvala L; Sloane S; Paulman R; Russell J; Hartman T; Ptak R Antiviral Res; 2004 Jan; 61(1):57-62. PubMed ID: 14670594 [TBL] [Abstract][Full Text] [Related]
19. Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. De Clercq E Adv Virus Res; 1993; 42():1-55. PubMed ID: 8430518 [TBL] [Abstract][Full Text] [Related]
20. Antiviral activity of cyclosaligenyl prodrugs of the nucleoside analogue bromovinyldeoxyuridine against herpes viruses. Meerbach A; Meier C; Sauerbrei A; Meckel HM; Wutzler P Int J Antimicrob Agents; 2006 May; 27(5):423-30. PubMed ID: 16621459 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]